Artwork

Content provided by Sage Publications and SAGE Publications Ltd.. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sage Publications and SAGE Publications Ltd. or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Tumori Journal – Author's Insight: A phase 2 study of cabozantinib for advanced renal cell carcinoma after immune-checkpoint inhibitors: the BREAKPOINT trial

9:26
 
Share
 

Manage episode 366256960 series 1022656
Content provided by Sage Publications and SAGE Publications Ltd.. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sage Publications and SAGE Publications Ltd. or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this podcast, Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial: a prospective, multicenter, single arm phase II trial evaluating efficacy and safety of cabozantinib for patients with metastatic renal cell carcinoma progressed after one line of treatment based on immune-checkpoints inhibitors.

  continue reading

154 episodes

Artwork
iconShare
 
Manage episode 366256960 series 1022656
Content provided by Sage Publications and SAGE Publications Ltd.. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sage Publications and SAGE Publications Ltd. or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this podcast, Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial: a prospective, multicenter, single arm phase II trial evaluating efficacy and safety of cabozantinib for patients with metastatic renal cell carcinoma progressed after one line of treatment based on immune-checkpoints inhibitors.

  continue reading

154 episodes

Все серии

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide